SCHEMBL8290476

SCHEMBL8290476

C/C(=N\NC(=O)c1cc(-c2ccccc2)n[nH]1)c1ccco1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.61
NPC1 O15118 7/20 0.60
RAB9A P51151 7/20 0.60
SMN1; SMN2 Q16637 4/20 0.57
PKM P14618 3/20 0.57
HPGD P15428 1/20 0.57
MAPK8 P45983 1/20 0.56
GAA P10253 2/20 0.55
CHEK1 O14757 1/20 0.54
RET P07949 1/20 0.54
PDGFRB P09619 1/20 0.54
PIM1 P11309 1/20 0.54
PDGFRA P16234 1/20 0.54
GSK3B P49841 1/20 0.54
RPS6KA3 P51812 1/20 0.54
LIMK1 P53667 1/20 0.54
CDK5 Q00535 1/20 0.54
TYRO3 Q06418 1/20 0.54
MAPK14 Q16539 1/20 0.54
LRRK2 Q5S007 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8290507 0.87 RAB9A (0.61) POLBNPC1RAB9ASMN1; SMN2PKM
SCHEMBL8292032 0.79 KMT2A (0.52) POLBNPC1RAB9ASMN1; SMN2PKM
SCHEMBL25467109 0.75 SPHK1 (0.83) RAB9AHPGDGAACHEK1RET
SCHEMBL30387984 0.75 SPHK1 (0.83) RAB9AHPGDGAACHEK1RET
SCHEMBL25292795 0.75 SPHK1 (0.83) RAB9AHPGDGAACHEK1RET
SCHEMBL9656234 0.73 POLB (0.69) POLBNPC1RAB9ASMN1; SMN2PKM
SCHEMBL9656226 0.73 POLB (0.69) POLBNPC1RAB9ASMN1; SMN2PKM
SCHEMBL10242682 0.71 TP53 (0.74) POLBMAPK8GAACHEK1RET
SCHEMBL7679430 0.71 RAB9A (0.60) POLBNPC1RAB9ASMN1; SMN2PKM
SCHEMBL7679429 0.71 RAB9A (0.60) POLBNPC1RAB9ASMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
WO-2005037257-A2 NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES IMTM GMBH (DE) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases DNPEP, PREP, ANPEP POLB 1250/4885NPC1 1326/4885RAB9A 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.